Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation

Cancer Lett. 2020 Mar 31:473:118-129. doi: 10.1016/j.canlet.2019.12.018. Epub 2019 Dec 13.

Abstract

Early studies suggest that the androgen receptor (AR) may play differential roles in influencing prostate cancer (PCa) and bladder cancer (BCa) metastasis, but the underlying mechanisms remain unclear. Here, we found that the AR might function via differentially altering vasculogenic mimicry (VM) formation to either decrease PCa metastasis or increase BCa metastasis. Mechanism dissection showed that the AR could differentially alter the expression of the VM marker SLPI through miR-525-5p to regulate SLPI; moreover, it could either increase miR-525-5p transcription in PCa or decrease it in BCa via binding to different androgen-response-elements (AREs) located at different positions in the miR-525 precursor promoter. Further, results from liquid chromatography-mass spectrometry (LC-MS) showed that the co-factors of AR in PCa and BCa are NFIX and HDAC2, respectively. Together, these results provide the first detailed mechanism of how the AR can differentially alter PCa and BCa metastasis; thus, targeting the newly identified AR-miR-525-5p-SLPI axis may help suppress metastasis.

Keywords: Androgen receptor; Bladder cancer; Prostate cancer; Vasculogenic mimicry; miRNA-525-5p.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androgen Antagonists / pharmacology
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Cell Line, Tumor
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Knockdown Techniques
  • Histone Deacetylase 2 / metabolism
  • Humans
  • Male
  • MicroRNAs / genetics*
  • NFI Transcription Factors / metabolism
  • Neoplasm Metastasis / genetics
  • Neoplasm Metastasis / prevention & control
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / genetics*
  • Neovascularization, Pathologic / prevention & control
  • Nitriles
  • Phenylthiohydantoin / analogs & derivatives
  • Phenylthiohydantoin / pharmacology
  • Phenylthiohydantoin / therapeutic use
  • Promoter Regions, Genetic / genetics
  • Prostatic Neoplasms / blood supply
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • RNA, Small Interfering / metabolism
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism*
  • Secretory Leukocyte Peptidase Inhibitor / genetics
  • Secretory Leukocyte Peptidase Inhibitor / metabolism*
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Transcription, Genetic / drug effects
  • Urinary Bladder Neoplasms / blood supply
  • Urinary Bladder Neoplasms / genetics*
  • Urinary Bladder Neoplasms / pathology

Substances

  • AR protein, human
  • Androgen Antagonists
  • Antineoplastic Agents
  • Benzamides
  • MIRN525 microRNA, human
  • MicroRNAs
  • NFI Transcription Factors
  • NFIX protein, human
  • Nitriles
  • RNA, Small Interfering
  • Receptors, Androgen
  • SLPI protein, human
  • Secretory Leukocyte Peptidase Inhibitor
  • Phenylthiohydantoin
  • enzalutamide
  • HDAC2 protein, human
  • Histone Deacetylase 2